Castres (France), February 19th 2016 - Pierre Fabre Laboratories (www.pierre-fabre.com), the 2nd largest French independent pharmaceutical group are pleased to announce that the management team of the Pierre Fabre Fund for Innovation will be attending the 4th annual Sachs Cancer Bio Partnering & Investment Forum that will be held in New York from the 24th of February.
The 4th Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech companies to facilitate partnering and funding/investment.
Dr Laurent AUDOLY, head of Pierre Fabre Pharmaceuticals R&D and managing partner at Pierre Fabre Fund for Innovation will be present at the conference “Early Stage Investment” chaired by Steve Dickman, chief executive officer of CBT Advisor, and scheduled for 4:00 PM on the 24th. In addition, Laurent AUDOLY and Vincent SERRA (executive partner at Pierre Fabre Fund for Innovation) will be available on Feb 23rd and Feb 24th to meet with interested parties including but not limited to investors and company representatives.
You can reach Laurent Audoly and Vincent Serra by mail at fund.for.innovation@pierre-fabre.com or by phone +33 (1) 785 861 303
About Pierre Fabre Fund for Innovation
Pierre Fabre Fund for Innovation is a new Open Innovation initiative launched by Pierre Fabre last January, targeting biotech companies, startups and research laboratories (public or private) specialized in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D.
Pierre Fabre Fund for Innovation will support R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. The support will consist of diverse forms of collaboration: sharing Pierre Fabre’s expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements. The combination of diverse forms of support is also conceivable. Pierre Fabre’s support on the long term will be conditioned to the reaching of key milestones in the innovation process. Open to all international partnership opportunities, the main goal for Pierre Fabre Fund for Innovation is to help innovative companies located in France or in Europe, at a time when many European biotech companies, startups and research laboratories often lack the internal capabilities and expertise to move from discovery to proof of concept, or lack financial resources to turn their projects into reality. Pierre Fabre’s expertise and capabilities made available to its future partners include pharmacology, new chemical entities, biotherapies, immunotherapy, translational medicine, preclinical and clinical development, production of clinical batches, market access as well as market and regulatory strategy.
About Pierre Fabre
Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1961 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Pierre Fabre’s oncology expertise is based on 3 decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. The company performs its oncology, onco-dermatology and dermatology R&D in two major research centres: the Pierre Fabre Immunology Centre (CIPF) based in Saint-Julien-en-Genevois (France) and the Pierre Fabre Research Institute (IRPF) located on the Toulouse-based Oncopole campus. The latter is officially recognized by the French government as a National Center of Excellence for cancer research.
Pierre Fabre laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm, ...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay,...), biotech companies (Array, BioPharma, AbCheck, Cellectar, ...) and international pharmaceutical laboratories (Allergan, Merck & Co., Abbvie, Maruho, ...).
Through the Group’s controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 7.8% of the remaining shares are held by the company’s employees and balance is held as treasury stock.
AFNOR Certification has assessed the Corporate Social Responsibility policy of Pierre Fabre as “exemplary” (AFAQ 26000).
To learn more, please go to www.pierre-fabre.com
